guselkumab vs tildrakizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT02203032 · Phase 3 · completed

In patients who had not responded well enough to ustekinumab, switching to guselkumab under randomized, blinded conditions produced significantly more visits with clear or almost-clear skin than staying on ustekinumab, a clinically meaningful and statistically significant result in a study designed and blinded to make that comparison fairly.

Next expected readout: December 2026 · NCT05004727 (registry estimate)

Reported efficacy

Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001. (met)

Result source: NCT02203032

tildrakizumab · Ilumya

Marketed by Sun Pharmaceutical Industries and partners

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT01729754 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (N=1,090) in moderate-to-severe plaque psoriasis. The primary efficacy endpoints, PASI-75 and PGA clear/minimal at Week 12, were both statistically significant in favor of tildrakizumab 200 mg and 100 mg compared with placebo (p<0.001). The strong design and positive primary results provide high-quality evidence of treatment benefit.

Next expected readout: September 2028 · NCT05390515 (registry estimate)

Reported efficacy

Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)); Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study) (Baseline and Week 12 (or end of trial if prior to Week 12)); Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study) (Up to 12 weeks): Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8% (met)

Result source: NCT01722331

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabtildrakizumab
PASI 7584.1% vs 6.3%+77.8 vs placebo100 mg · wk 16 · n 63NCT02325219
11 other results
  • 89.2% vs 6.3% 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • 86.3% vs 68.5% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 92.7% vs 92.8% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 89.3% vs 91.6% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 91.2% vs 73.1% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 78.6% vs 4.8% 100 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 50 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 200 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 75.6% vs 4.8% 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 43.9% vs 4.8% 5 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 5.1% vs 22.9% wk 2 · n 507 · Phase 4 · secondary NCT03573323
66.3% vs 4.4%+61.9 vs placebo100 mg · wk 16 · n 89NCT01225731
31 other results
  • 74.4% vs 4.4% 200 mg · wk 16 · n 86 · Phase 2 · primary NCT01225731
  • 64.4% vs 4.4% 25 mg · wk 16 · n 90 · Phase 2 · primary NCT01225731
  • 33.3% vs 4.4% 5 mg · wk 16 · n 42 · Phase 2 · primary NCT01225731
  • 67.0% vs 4.9% 100 mg · wk 16 · n 89 · Phase 2 · secondary NCT01225731
  • 60.7% vs 4.4% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 61.4% vs 4.8% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 47.1% vs 4.7% 100 mg · wk 8 · n 89 · Phase 2 · secondary NCT01225731
  • 25% vs 2.3% 100 mg · wk 6 · n 89 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 100 mg · wk 4 · n 89 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 100 mg · wk 2 · n 89 · Phase 2 · secondary NCT01225731
  • 76.2% vs 4.9% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 72.1% vs 4.4% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 73.5% vs 4.8% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 61.5% vs 4.7% 200 mg · wk 8 · n 86 · Phase 2 · secondary NCT01225731
  • 30.9% vs 2.3% 200 mg · wk 6 · n 86 · Phase 2 · secondary NCT01225731
  • 3.5% vs 0% 200 mg · wk 4 · n 86 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 200 mg · wk 2 · n 86 · Phase 2 · secondary NCT01225731
  • 65.5% vs 4.9% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 58.9% vs 4.4% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 59.8% vs 4.8% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 35.2% vs 4.7% 25 mg · wk 8 · n 90 · Phase 2 · secondary NCT01225731
  • 20.9% vs 2.3% 25 mg · wk 6 · n 90 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 25 mg · wk 4 · n 90 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 25 mg · wk 2 · n 90 · Phase 2 · secondary NCT01225731
  • 35% vs 4.9% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731
  • 23.8% vs 4.4% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 25% vs 4.8% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 4.7% 5 mg · wk 8 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.3% 5 mg · wk 6 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 4 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 2 · n 42 · Phase 2 · secondary NCT01225731
PASI 9070% vs 2.4%+67.6 vs placebo100 mg · wk 16 · n 496NCT02207244
10 other results
  • 73.3% vs 2.9% wk 16 · n 329 · Phase 3 · primary NCT02207231
  • 69.8% vs 0% 100 mg · wk 16 · n 63 · Phase 3 · primary NCT02325219
  • 70.8% vs 0% 50 mg · wk 16 · n 65 · Phase 3 · primary NCT02325219
  • 75.8% vs 0% wk 16 · n 62 · Phase 3 · primary NCT02905331
  • 70% vs 46.8% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 78.5% vs 79.6% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 69.1% vs 76.1% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 73.3% vs 49.7% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 35.9% vs 58.5% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 7.9% vs 21% wk 4 · n 507 · Phase 4 · secondary NCT03573323
38.6% vs 2.4%+36.2 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 52.4% vs 2.4% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 25.3% vs 2.4% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.4% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731
PASI 10050% vs 0%+50 vs placebowk 16 · n 62NCT02905331
3 other results
  • 24.9% vs 41.3% wk 12 · n 507 · Phase 4 · primary NCT03573323
  • 13.6% vs 29.6% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 1.4% vs 6.7% wk 4 · n 507 · Phase 4 · secondary NCT03573323
14.8% vs 0%+14.8 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 16.7% vs 0% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 9.2% vs 0% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 5% vs 0% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731
sPGA 0/185.7% vs 7.1%+78.6 vs placebo100 mg · wk 16 · n 42NCT01483599
4 other results
  • 78.6% vs 7.1% 50 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 83.3% vs 7.1% 200 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 61% vs 7.1% 15 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
  • 34.1% vs 7.1% 5 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
61.8% vs 2.2%+59.6 vs placebo100 mg · wk 16 · n 89NCT01225731
3 other results
  • 74.4% vs 2.2% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 57.8% vs 2.2% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 33.3% vs 2.2% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731
DLQI, change-11.2 vs -2.6−8.6 vs placebo100 mg · wk 16 · n 495NCT02207244
10 other results
  • -11.2 vs -0.6 wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • -8.5 vs -0.8 100 mg · wk 16 · n 63 · Phase 3 · secondary NCT02325219
  • -7 vs -0.4 100 mg · wk 8 · n 63 · Phase 3 · secondary NCT02325219
  • -8.3 vs -0.8 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • -7.5 vs -0.4 50 mg · wk 8 · n 65 · Phase 3 · secondary NCT02325219
  • -10.8 vs -2.3 100 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.1 vs -2.3 50 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.4 vs -2.3 200 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
  • -10.3 vs -2.3 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • -6.2 vs -2.3 5 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
-8.5 vs 1−9.5 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • -8.8 vs 1 200 mg · wk 16 · n 83 · Phase 2 · secondary NCT01225731
  • -9.2 vs 1 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • -4.9 vs 1 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731

PASI 75

guselkumab
84.1% vs 6.3%+77.8 vs placebo100 mg · wk 16 · n 63NCT02325219
11 other results
  • 89.2% vs 6.3% 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • 86.3% vs 68.5% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 92.7% vs 92.8% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 89.3% vs 91.6% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 91.2% vs 73.1% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 78.6% vs 4.8% 100 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 50 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 200 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 75.6% vs 4.8% 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 43.9% vs 4.8% 5 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 5.1% vs 22.9% wk 2 · n 507 · Phase 4 · secondary NCT03573323
tildrakizumab
66.3% vs 4.4%+61.9 vs placebo100 mg · wk 16 · n 89NCT01225731
31 other results
  • 74.4% vs 4.4% 200 mg · wk 16 · n 86 · Phase 2 · primary NCT01225731
  • 64.4% vs 4.4% 25 mg · wk 16 · n 90 · Phase 2 · primary NCT01225731
  • 33.3% vs 4.4% 5 mg · wk 16 · n 42 · Phase 2 · primary NCT01225731
  • 67.0% vs 4.9% 100 mg · wk 16 · n 89 · Phase 2 · secondary NCT01225731
  • 60.7% vs 4.4% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 61.4% vs 4.8% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 47.1% vs 4.7% 100 mg · wk 8 · n 89 · Phase 2 · secondary NCT01225731
  • 25% vs 2.3% 100 mg · wk 6 · n 89 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 100 mg · wk 4 · n 89 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 100 mg · wk 2 · n 89 · Phase 2 · secondary NCT01225731
  • 76.2% vs 4.9% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 72.1% vs 4.4% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 73.5% vs 4.8% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 61.5% vs 4.7% 200 mg · wk 8 · n 86 · Phase 2 · secondary NCT01225731
  • 30.9% vs 2.3% 200 mg · wk 6 · n 86 · Phase 2 · secondary NCT01225731
  • 3.5% vs 0% 200 mg · wk 4 · n 86 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 200 mg · wk 2 · n 86 · Phase 2 · secondary NCT01225731
  • 65.5% vs 4.9% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 58.9% vs 4.4% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 59.8% vs 4.8% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 35.2% vs 4.7% 25 mg · wk 8 · n 90 · Phase 2 · secondary NCT01225731
  • 20.9% vs 2.3% 25 mg · wk 6 · n 90 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 25 mg · wk 4 · n 90 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 25 mg · wk 2 · n 90 · Phase 2 · secondary NCT01225731
  • 35% vs 4.9% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731
  • 23.8% vs 4.4% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 25% vs 4.8% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 4.7% 5 mg · wk 8 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.3% 5 mg · wk 6 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 4 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 2 · n 42 · Phase 2 · secondary NCT01225731

PASI 90

guselkumab
70% vs 2.4%+67.6 vs placebo100 mg · wk 16 · n 496NCT02207244
10 other results
  • 73.3% vs 2.9% wk 16 · n 329 · Phase 3 · primary NCT02207231
  • 69.8% vs 0% 100 mg · wk 16 · n 63 · Phase 3 · primary NCT02325219
  • 70.8% vs 0% 50 mg · wk 16 · n 65 · Phase 3 · primary NCT02325219
  • 75.8% vs 0% wk 16 · n 62 · Phase 3 · primary NCT02905331
  • 70% vs 46.8% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 78.5% vs 79.6% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 69.1% vs 76.1% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 73.3% vs 49.7% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 35.9% vs 58.5% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 7.9% vs 21% wk 4 · n 507 · Phase 4 · secondary NCT03573323
tildrakizumab
38.6% vs 2.4%+36.2 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 52.4% vs 2.4% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 25.3% vs 2.4% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.4% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731

PASI 100

guselkumab
50% vs 0%+50 vs placebowk 16 · n 62NCT02905331
3 other results
  • 24.9% vs 41.3% wk 12 · n 507 · Phase 4 · primary NCT03573323
  • 13.6% vs 29.6% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 1.4% vs 6.7% wk 4 · n 507 · Phase 4 · secondary NCT03573323
tildrakizumab
14.8% vs 0%+14.8 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 16.7% vs 0% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 9.2% vs 0% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 5% vs 0% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731

sPGA 0/1

guselkumab
85.7% vs 7.1%+78.6 vs placebo100 mg · wk 16 · n 42NCT01483599
4 other results
  • 78.6% vs 7.1% 50 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 83.3% vs 7.1% 200 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 61% vs 7.1% 15 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
  • 34.1% vs 7.1% 5 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
tildrakizumab
61.8% vs 2.2%+59.6 vs placebo100 mg · wk 16 · n 89NCT01225731
3 other results
  • 74.4% vs 2.2% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 57.8% vs 2.2% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 33.3% vs 2.2% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731

DLQI, change

guselkumab
-11.2 vs -2.6−8.6 vs placebo100 mg · wk 16 · n 495NCT02207244
10 other results
  • -11.2 vs -0.6 wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • -8.5 vs -0.8 100 mg · wk 16 · n 63 · Phase 3 · secondary NCT02325219
  • -7 vs -0.4 100 mg · wk 8 · n 63 · Phase 3 · secondary NCT02325219
  • -8.3 vs -0.8 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • -7.5 vs -0.4 50 mg · wk 8 · n 65 · Phase 3 · secondary NCT02325219
  • -10.8 vs -2.3 100 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.1 vs -2.3 50 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.4 vs -2.3 200 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
  • -10.3 vs -2.3 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • -6.2 vs -2.3 5 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
tildrakizumab
-8.5 vs 1−9.5 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • -8.8 vs 1 200 mg · wk 16 · n 83 · Phase 2 · secondary NCT01225731
  • -9.2 vs 1 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • -4.9 vs 1 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety

Coverage. guselkumab: 12 of 12 rows · tildrakizumab: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumab
Rows use multiple source trials
tildrakizumab
Rows use multiple source trials
BSA
absolute change · percentage points
No placebo or comparator arm
-25.1% (n=141) @ 52wk100 mg Q8Wa,b,c,d
NCT03818035 · Phase 3 · registry result, not featured evidence
show 2 more doses
-24.8% (n=492) @ 52wk100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
-24.3% (n=142) @ 52wk100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
-11.5% (n=55) @ 52wk100 mgb,c,d
NCT03718299 · Phase 4 · registry result, not featured evidence
DLQI
absolute change · score
No placebo or comparator arm
5.3 score @ 100wkb,c,d,e
NCT02951533 · Phase 3 · registry result, not featured evidence
-8 score @ 64wk100 mgb,c,d,e
NCT03718299 · Phase 4 · registry result, not featured evidence
DLQI 0/1
responder rate · % of participants
No placebo or comparator arm
76.7% (n=60) @ 52wk100 mga,b,c,d
NCT02325219 · Phase 3 · registry result, not featured evidence
show 1 more dose
73.4% (n=64) @ 52wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
56.3% (n=55) @ 52wk100 mgb,c,d
NCT03718299 · Phase 4 · registry result, not featured evidence
DLQI 5 Point Improvement
responder rate · % of participants
Induction
69.8% (n=63) vs 20.3% (n=64) placebo @ 16wk100 mga,f,c,d
NCT02325219 · Phase 3 · registry result, not featured evidence
show 1 more dose
67.7% (n=65) vs 20.3% (n=64) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
64.77% (n=88) vs 19.05% (n=42) placebo @ 16wk100 mga,f,c,d
NCT01225731 · Phase 2 · registry result, not featured evidence
show 3 more doses
73.49% (n=83) vs 19.05% (n=42) placebo @ 16wk200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
70.11% (n=87) vs 19.05% (n=42) placebo @ 16wk25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
52.5% (n=40) vs 19.05% (n=42) placebo @ 16wk5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
DLQI 5 Point Improvement
responder rate · % of participants
No placebo or comparator arm
71.4% (n=63) @ 52wk100 mga,b,c,d
NCT02325219 · Phase 3 · registry result, not featured evidence
show 1 more dose
72.3% (n=65) @ 52wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
82.5% (n=55) @ 52wk100 mgb,c,d
NCT03718299 · Phase 4 · registry result, not featured evidence
PASI
absolute change · score
Induction
-23.9 vs -0.5 placebo score @ 16wk100 mga,f,c,d
NCT02325219 · Phase 3 · registry result, not featured evidence
show 1 more dose
-22.6 vs -0.5 placebo score @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-14.9 vs -2.4 placebo score @ 16wk100 mga,f,c,d
NCT01225731 · Phase 2 · registry result, not featured evidence
show 3 more doses
-15.6 vs -2.4 placebo score @ 16wk200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
-14.6 vs -2.4 placebo score @ 16wk25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
-10 vs -2.4 placebo score @ 16wk5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
PASI
absolute change · score
No placebo or comparator arm
-24.6 score @ 52wk100 mga,b,c,d
NCT02325219 · Phase 3 · registry result, not featured evidence
show 1 more dose
-23.5 score @ 52wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-10 score @ 52wk100 mgb,c,d
NCT03718299 · Phase 4 · registry result, not featured evidence
PASI 50
responder rate · % of participants
Induction
9.3% (n=507) vs 27.5% (n=520) Ixekizumab @ 1wkg,c,d,h
NCT03573323 · Phase 4 · registry result, not featured evidence
82.02% (n=89) vs 8.89% (n=45) placebo @ 16wk100 mga,g,c,d,h
NCT01225731 · Phase 2 · registry result, not featured evidence
show 3 more doses
91.86% (n=86) vs 8.89% (n=45) placebo @ 16wk200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
82.22% (n=90) vs 8.89% (n=45) placebo @ 16wk25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
57.14% (n=42) vs 8.89% (n=45) placebo @ 16wk5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Dropout rate
—100 mgi
NCT02203032 · Phase 3
show 42 more results
3.6%100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207231 · Phase 3
—100 mg
NCT02207231 · Phase 3
1.6%Guselkumab
NCT02905331 · Phase 3
—Guselkumab (Week 0-16)
NCT02905331 · Phase 3
—Guselkumab (Week 16-40)
NCT02905331 · Phase 3
9.5%
NCT03573323 · Phase 4 · registry result, not featured evidence
13%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
4.9%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
7.6%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
6.6%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.6%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
3.1%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
5.1%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
4.8%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
9.5%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.3%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—100 mgi
NCT01729754 · Phase 3 · monotherapy
show 24 more results
—200 mg
NCT01729754 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
15.7%100 mg
NCT03897075 · Phase 3
—100 mg
NCT03897075 · Phase 3
16.7%
NCT04271540 · Phase 4 · registry result, not featured evidence
0%
NCT04541329 · Phase 4 · registry result, not featured evidence
18.2%100 mg
NCT03718299 · Phase 4 · registry result, not featured evidence
1.1%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.3%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
5.4%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
4.8%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—100 mgi
NCT02203032 · Phase 3
show 42 more results
1.8%100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207231 · Phase 3
—100 mg
NCT02207231 · Phase 3
0%Guselkumab
NCT02905331 · Phase 3
—Guselkumab (Week 0-16)
NCT02905331 · Phase 3
—Guselkumab (Week 16-40)
NCT02905331 · Phase 3
1.6%
NCT03573323 · Phase 4 · registry result, not featured evidence
1.3%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
1.9%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
1.7%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
2.4%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
2.4%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
9.5%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—100 mgi
NCT01729754 · Phase 3 · monotherapy
show 24 more results
—200 mg
NCT01729754 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT03897075 · Phase 3
—100 mg
NCT03897075 · Phase 3
—
NCT04271540 · Phase 4 · registry result, not featured evidence
—
NCT04541329 · Phase 4 · registry result, not featured evidence
1.8%100 mg
NCT03718299 · Phase 4 · registry result, not featured evidence
1.1%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.2%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.2%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.4%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Serious AEs
6.7%100 mgi
NCT02203032 · Phase 3
show 42 more results
1.6%100 mg
NCT02207244 · Phase 3
2.1%100 mg
NCT02207244 · Phase 3
14%100 mg
NCT02207244 · Phase 3
2.5%100 mg
NCT02207231 · Phase 3
2.4%100 mg
NCT02207231 · Phase 3
—Guselkumab
NCT02905331 · Phase 3
3.2%Guselkumab (Week 0-16)
NCT02905331 · Phase 3
1.6%Guselkumab (Week 16-40)
NCT02905331 · Phase 3
3.2%
NCT03573323 · Phase 4 · registry result, not featured evidence
3.9%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
3.7%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
5.3%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
4.7%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
6.3%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
2.2%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
3.5%100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
4.3%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
0%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
4%100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
6.6%100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
9.7%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.6%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
9.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
5%Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
0%Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
5.5%Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
6.2%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
5%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
5.3%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
6.2%100 mgi
NCT01729754 · Phase 3 · monotherapy
show 24 more results
4.9%200 mg
NCT01729754 · Phase 3 · monotherapy
1.6%100 mg
NCT01722331 · Phase 3 · monotherapy
1.9%100 mg
NCT01722331 · Phase 3 · monotherapy
4.4%100 mg
NCT01722331 · Phase 3 · monotherapy
2.6%200 mg
NCT01722331 · Phase 3 · monotherapy
2.2%200 mg
NCT01722331 · Phase 3 · monotherapy
5.8%200 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT03897075 · Phase 3
5.9%100 mg
NCT03897075 · Phase 3
0%
NCT04271540 · Phase 4 · registry result, not featured evidence
0%
NCT04541329 · Phase 4 · registry result, not featured evidence
7.3%100 mg
NCT03718299 · Phase 4 · registry result, not featured evidence
1.1%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
3.9%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.5%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.3%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
3.8%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.7%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.1%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
5.3%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.1%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mgi
nasopharyngitis 17%
upper respiratory tract infection 11.1%
NCT02203032 · Phase 3
show 37 more results
100 mg
nasopharyngitis 7.1% (placebo 6.5%)
headache 5.1% (placebo 2.8%)
upper respiratory tract infection 3.2% (placebo 4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 3.7% (placebo 6.5%)
upper respiratory tract infection 2.5% (placebo 4%)
arthralgia 1.7% (placebo 2.4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 30% (placebo 6.5%)
upper respiratory tract infection 23.5% (placebo 4%)
arthralgia 9.7% (placebo 2.4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 20.1% (placebo 9.8%)
upper respiratory tract infection 9.6% (placebo 5.2%)
gastroenteritis 3.4% (placebo 1.1%)
NCT02207231 · Phase 3
100 mg
nasopharyngitis 9.1% (placebo 9.8%)
upper respiratory tract infection 7.6% (placebo 5.2%)
headache 4.3% (placebo 4%)
NCT02207231 · Phase 3
injection site pain 40.3% (placebo 43.8%)
injection site coldness 22.6% (placebo 18.8%)
injection site pruritus 12.9% (placebo 12.5%)
NCT02905331 · Phase 3
injection site pain 18% (placebo 43.8%)
injection site coldness 11.5% (placebo 18.8%)
viral upper respiratory tract infection 9.8% (placebo 0%)
NCT02905331 · Phase 3
upper respiratory tract infection 8.1%
nasopharyngitis 5.3%
injection site reaction 1.2%
NCT03573323 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 16.9% (placebo 3.8%)
nasopharyngitis 11.7% (placebo 3.8%)
covid-19 6.5% (placebo 0%)
NCT05272150 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 24.7% (placebo 3.8%)
covid-19 16% (placebo 0%)
arthralgia 7.4% (placebo 0%)
NCT05272150 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 15.1% (placebo 2.7%)
nasopharyngitis 6.7% (placebo 7.1%)
covid-19 4.4% (placebo 0.9%)
NCT06039189 · Phase 3 · registry result, not featured evidence
100 mg Q8W
nasopharyngitis 17.6%
headache 5.4%
back pain 4.1%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q8W
nasopharyngitis 18.5%
hypertension 5.9%
arthralgia 5.5%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q8W
covid-19 14.7%
nasopharyngitis 12.5%
psoriasis 7.4%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 14.1%
covid-19 9.3%
headache 5.7%
NCT03818035 · Phase 3 · registry result, not featured evidence
100mg
nasopharyngitis 24.3%
headache 9%
hypertension 5.5%
NCT03818035 · Phase 3 · registry result, not featured evidence
100mg
nail psoriasis 22.2%
back pain 11.1%
covid-19 11.1%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q16W
nasopharyngitis 15.4%
headache 6%
back pain 5.4%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q16W
nasopharyngitis 12.4%
covid-19 8.8%
psoriasis 8.8%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 50% (placebo 10.9%)
eczema 11.3% (placebo 1.6%)
injection site erythema 11.3% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 12.7% (placebo 10.9%)
dental caries 3.2% (placebo 1.6%)
upper respiratory tract infection 3.2% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
50 mg
nasopharyngitis 60.3% (placebo 10.9%)
arthralgia 14.3% (placebo 0%)
influenza 14.3% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
50 mg
nasopharyngitis 21.5% (placebo 10.9%)
alopecia 3.1% (placebo 0%)
arthralgia 3.1% (placebo 0%)
NCT02325219 · Phase 3 · registry result, not featured evidence
nasopharyngitis 41.7%
headache 15%
diarrhoea 11.7%
NCT02951533 · Phase 3 · registry result, not featured evidence
aspartate aminotransferase increased 2.8%
tooth infection 2.8%
abdominal discomfort 0%
NCT02951533 · Phase 3 · registry result, not featured evidence
nasopharyngitis 50.9%
bronchitis 9.1%
alanine aminotransferase increased 5.5%
NCT02951533 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 22.1%
upper respiratory tract infection 15.5%
headache 9%
NCT03090100 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 10% (placebo 2.4%)
upper respiratory tract infection 7.5% (placebo 2.4%)
back pain 5% (placebo 0%)
NCT01483599 · Phase 2 · registry result, not featured evidence
100 mg
back pain 4.8% (placebo 0%)
headache 4.8% (placebo 2.4%)
sinusitis 4.8% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
50 mg
nasopharyngitis 17.9% (placebo 2.4%)
back pain 2.6% (placebo 0%)
headache 2.6% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
50 mg
hypertension 7.1% (placebo 2.4%)
fatigue 4.8% (placebo 7.1%)
arthralgia 2.4% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 13.2% (placebo 2.4%)
cough 5.3% (placebo 2.4%)
upper respiratory tract infection 5.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
200 mg
upper respiratory tract infection 7.3% (placebo 2.4%)
cough 4.9% (placebo 2.4%)
nasopharyngitis 4.9% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
15 mg
back pain 2.4% (placebo 0%)
nasopharyngitis 2.4% (placebo 2.4%)
sinusitis 2.4% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
15 mg
headache 9.8% (placebo 2.4%)
nasopharyngitis 9.8% (placebo 2.4%)
back pain 2.4% (placebo 0%)
NCT01483599 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 15.8% (placebo 2.4%)
upper respiratory tract infection 10.5% (placebo 2.4%)
arthralgia 5.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 14.6% (placebo 2.4%)
back pain 7.3% (placebo 0%)
headache 7.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
100 mgi
nasopharyngitis 23% (placebo 7.7%)
headache 6% (placebo 3.8%)
arthralgia 5.3% (placebo 1.9%)
NCT01729754 · Phase 3 · monotherapy
show 22 more results
200 mg
nasopharyngitis 22.6% (placebo 7.7%)
headache 5.7% (placebo 3.8%)
upper respiratory tract infection 5.1% (placebo 0.6%)
NCT01729754 · Phase 3 · monotherapy
100 mg
nasopharyngitis 7.8% (placebo 5.2%)
upper respiratory tract infection 3.2% (placebo 5.8%)
psoriasis 0.6% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
100 mg
nasopharyngitis 6.4% (placebo 5.2%)
upper respiratory tract infection 4.3% (placebo 5.8%)
psoriasis 0.5% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
100 mg
nasopharyngitis 15.2% (placebo 5.2%)
upper respiratory tract infection 8.2% (placebo 5.8%)
psoriasis 2.8% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
200 mg
nasopharyngitis 6.5% (placebo 5.2%)
upper respiratory tract infection 4.9% (placebo 5.8%)
psoriasis 0% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
200 mg
upper respiratory tract infection 5.4% (placebo 5.8%)
nasopharyngitis 4.6% (placebo 5.2%)
psoriasis 0.8% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
200 mg
nasopharyngitis 12.2% (placebo 5.2%)
upper respiratory tract infection 10.3% (placebo 5.8%)
psoriasis 2.5% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
100 mg
covid-19 11.8% (placebo 10.4%)
skin and subcutaneous tissue disorders 9.8% (placebo 4.2%)
upper respiratory tract infection 9.8% (placebo 8.3%)
NCT03897075 · Phase 3
covid infection 9.7%
NCT04271540 · Phase 4 · registry result, not featured evidence
100 mg
psoriasis 12.7%
hypertension 9.1%
dermatitis 5.5%
NCT03718299 · Phase 4 · registry result, not featured evidence
100 mg
nasopharyngitis 14.6% (placebo 20%)
diarrhoea 6.7% (placebo 6.7%)
headache 6.7% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 22.2% (placebo 20%)
headache 8.5% (placebo 8.9%)
back pain 5.2% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 8.8% (placebo 20%)
back pain 3.6% (placebo 0%)
headache 3.6% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 12.8% (placebo 20%)
headache 8.1% (placebo 8.9%)
pruritus 4.7% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 16.5% (placebo 20%)
gastroenteritis 6.3% (placebo 2.2%)
upper respiratory tract infection 5.1% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 6.7% (placebo 20%)
upper respiratory tract infection 4% (placebo 0%)
bronchiitis 2.7% (placebo 4.4%)
NCT01225731 · Phase 2 · registry result, not featured evidence
25 mg
nasopharyngitis 13.2% (placebo 20%)
diarrhoea 5.5% (placebo 6.7%)
headache 5.5% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
25 mg
nasopharyngitis 25.5% (placebo 20%)
gastroenteritis 5.3% (placebo 2.2%)
back pain 4.3% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
25 mg
nasopharyngitis 6.9% (placebo 20%)
back pain 3.4% (placebo 0%)
bronchiitis 2.3% (placebo 4.4%)
NCT01225731 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 16.7% (placebo 20%)
bronchiitis 7.1% (placebo 4.4%)
cough 7.1% (placebo 4.4%)
NCT01225731 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 23.1% (placebo 20%)
acute tonsilitis 7.7% (placebo 0%)
blood pressure systolic increased 7.7% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain upper 8.3% (placebo 0%)
back pain 8.3% (placebo 0%)
dyspnoea 8.3% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 4.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 100 weeks versus 64 weeks.
  6. fTrial phases differ: Phase 3 versus Phase 2.
  7. gTrial phases differ: Phase 4 versus Phase 2.
  8. hAssessment timepoints differ: 1 weeks versus 16 weeks.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

IGA 0 1 Response Visits 1.5 vs 0.7 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
PASI90 Response Visits 2.2 vs 1.1 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
IGA 0 Response Visits 0.9 vs 0.4 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
IGA 0/1 84.1% (n=496) vs 8.5% (n=248) placebo @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 13 more results
83.5% (n=496) vs 64.9% (n=248) Adalimumab @ 24wk100 mg
NCT02207244 · Phase 3
84.1% (n=496) vs 67.7% (n=248) Adalimumab @ 16wk100 mg
NCT02207244 · Phase 3
88.9% (n=63) vs 7.8% (n=64) placebo @ 16wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
85% (n=534) vs 74.9% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
86.7% (n=534) vs 86.6% (n=514) Secukinumab @ 16wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
85.6% (n=534) vs 86.4% (n=514) Secukinumab @ 12wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
92.3% (n=65) vs 7.8% (n=64) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
31.1% (n=135) vs 14.3% (n=133) Ustekinumab @ 28wk
NCT02203032 · Phase 3
85.1% (n=329) vs 6.9% (n=174) placebo @ 16wk
NCT02207231 · Phase 3
84.2% (n=329) vs 61.7% (n=334) Adalimumab @ 24wk
NCT02207231 · Phase 3
80.5% (n=329) vs 55.4% (n=334) Adalimumab @ 48wk
NCT02207231 · Phase 3
85.1% (n=329) vs 65.9% (n=334) Adalimumab @ 16wk
NCT02207231 · Phase 3
80.6% (n=62) vs 0% (n=16) placebo @ 16wk
NCT02905331 · Phase 3
IGA 0 51.8% (n=496) vs 31.5% (n=248) Adalimumab @ 24wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 5 more results
62.2% (n=534) vs 50.4% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
52.6% (n=329) vs 29.3% (n=334) Adalimumab @ 24wk
NCT02207231 · Phase 3
50.5% (n=329) vs 25.7% (n=334) Adalimumab @ 48wk
NCT02207231 · Phase 3
56.5% (n=62) vs 0% (n=16) placebo @ 16wk
NCT02905331 · Phase 3
51.7% (n=60) vs 6.8% (n=59) Fumaric Acid Esters @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
PASI 90 Response Maintenance 72.3% (n=534) vs 64.4% (n=514) Secukinumab @ 48wk100 mg
responder rate · % of participants
NCT03090100 · Phase 3 · registry result, not featured evidence
show 5 more results
71% (n=534) vs 61.5% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
92.1% (n=419) vs 80.9% (n=409) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
81.8% (n=193) vs 35.4% (n=181) placebo @ 48wk
NCT02207244 · Phase 3
86% (n=193) vs 11.5% (n=181) placebo @ 72wk
NCT02207244 · Phase 3
85.2% (n=54) vs 35.7% (n=14) Fumaric Acid Esters @ 56wk
NCT02951533 · Phase 3 · registry result, not featured evidence
Ss-IGA 0 1 80.6% (n=408) vs 10.9% (n=202) placebo @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 1 more result
83.4% (n=277) vs 14.5% (n=145) placebo @ 16wk
NCT02207231 · Phase 3
PSSD Symptom -40.4 vs -8.3 placebo score @ 16wk100 mg
absolute change · score
NCT02207244 · Phase 3
show 1 more result
-41.9 vs -3 placebo score @ 16wk
NCT02207231 · Phase 3
PSSD Symptom Score 0 35.1% (n=410) vs 22.5% (n=200) Adalimumab @ 24wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 1 more result
36.3% (n=248) vs 21.6% (n=273) Adalimumab @ 24wk
NCT02207231 · Phase 3
IGA Leq2 93.5% (n=62) vs 0% (n=16) placebo @ 16wk
responder rate · % of participants
NCT02905331 · Phase 3
PASI 50 93.5% (n=62) vs 0% (n=16) placebo @ 16wk
responder rate · % of participants
PASI 50 responders
NCT02905331 · Phase 3
PASI 75 88.7% (n=62) vs 0% (n=16) placebo @ 16wk
responder rate · % of participants
PASI 75 responders
NCT02905331 · Phase 3

+ 86 further endpoints in the CSV export.

tildrakizumab

PASI 75 61.2% (n=307) vs 5.8% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
73.5% (n=294) vs 53.6% (n=289) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
63.8% (n=309) vs 5.8% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
65.6% (n=314) vs 5.8% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
72.6% (n=299) vs 53.6% (n=289) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
62.3% (n=308) vs 5.8% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
sPGA 0/1 54.7% (n=307) vs 4.5% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
64.6% (n=294) vs 45.3% (n=289) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
57.9% (n=309) vs 7.1% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
59.2% (n=314) vs 4.5% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
69.2% (n=299) vs 45.3% (n=289) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
59.1% (n=308) vs 7.1% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
PASI 75 97.6% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
66.7% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
61.9% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
93.6% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
78.9% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
68.4% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
96.3% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
92.6% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
63.3% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
97.1% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
94.2% (n=104) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
66.7% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
sPGA 0/1 84.9% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
38.1% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
57.1% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
79.4% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
42.1% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
57.9% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
83.2% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
79.2% (n=106) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
57.6% (n=59) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
84.8% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
77.7% (n=103) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
50.8% (n=59) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
PASI 90 38.8% (n=307) vs 1.3% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
55.5% (n=290) vs 30.7% (n=277) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
34.6% (n=309) vs 2.6% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
36.6% (n=314) vs 1.3% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
57.7% (n=293) vs 30.7% (n=277) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
35.4% (n=308) vs 2.6% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
PASI 90 78.8% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
23.8% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
42.9% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
78.4% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
26.3% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
42.1% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
76.6% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
73.1% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
28.3% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
81.9% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
68.3% (n=104) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
31.7% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
PASI 100 12.4% (n=307) vs 0% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
22.8% (n=290) vs 11.2% (n=277) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
13.9% (n=309) vs 1.3% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
11.8% (n=314) vs 0% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
27% (n=293) vs 11.2% (n=277) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
14% (n=308) vs 1.3% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
PASI 100 33.5% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
0% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
14.3% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
35.3% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
5.3% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
31.6% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
39.3% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
38.9% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
11.7% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
46.7% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
37.5% (n=104) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
10% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
DLQI -10.2 vs -2 placebo score @ 12wk100 mg
absolute change · score
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
-11.2 vs -9.5 Etanercept score @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
-9.8 vs -2.3 placebo score @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
-10.3 vs -2 placebo score @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
-11.7 vs -9.5 Etanercept score @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
-10 vs -2.3 placebo score @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
DLQI -13.2 score @ 40wk100 mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
-9 score @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
-9.8 score @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
-13.1 score @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
-9.4 score @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
-9.3 score @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
-11.6 score @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
-12 score @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
-9.7 score @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
-11.3 score @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
-11.5 score @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
-9.2 score @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
DLQI 0/1 40.2% (n=296) vs 8% (n=150) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
54.1% (n=290) vs 39.4% (n=282) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
41.5% (n=304) vs 5.3% (n=150) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
47.4% (n=306) vs 8% (n=150) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
65% (n=297) vs 39.4% (n=282) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
44.2% (n=299) vs 5.3% (n=150) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
DLQI 0/1 71.2% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
9.5% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
19% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
68.8% (n=205) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
10.5% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
42.1% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
72.2% (n=108) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
68.5% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
41.7% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
72.4% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
71.4% (n=105) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
40% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy

+ 20 further endpoints in the CSV export.

Psoriatic Arthritis

Shared mechanism: IL-23 p19 · full Psoriatic Arthritis pipeline

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Psoriatic Arthritismonoclonal antibody
Reliable signal

NCT03162796 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial, and both guselkumab doses beat placebo on the week-24 ACR20 joint response (p<0.001). The protocol's sample-size calculation called for 360 patients, and 383 were enrolled.

Next expected readout: April 2027 · NCT04929210 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants (met)

Result source: NCT04882098

tildrakizumab · Ilumya

Marketed by Sun Pharmaceutical Industries and partners

Approved in Psoriatic Arthritismonoclonal antibody
Partial signal

NCT04314544 · Phase 3 · completed

The study randomized 508 participants to tildrakizumab or placebo, with outcome assessors masked, and used the clinical ACR20 response as its primary endpoint. However, no results are posted, so whether the primary endpoint was met or missed is unknown.

Next expected readout: December 2028 · NCT04991116 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointguselkumabtildrakizumab
ACR2052% vs 22.2%+29.8 vs placebo100 mg q8w · wk 24 · n 127NCT03162796
27 other results
  • 59.4% vs 22.2% 100 mg q4w · wk 24 · n 128 · Phase 3 · primary NCT03162796
  • 52% vs 22.2% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 59.4% vs 22.2% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 54.5% vs 27.2% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 60.8% vs 27.2% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 51.2% vs 30.2% 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • 62.5% vs 30.2% 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • 68.9% vs 50% 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • 74.4% vs 50% 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • 52% vs 25.4% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 60.2% vs 25.4% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 52% vs 25.4% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 60.2% vs 25.4% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 43.3% vs 27% 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • 53.1% vs 27% 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • 70.3% vs 56.9% 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • 71.1% vs 56.9% 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • 36.2% vs 18.3% 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • 39.1% vs 18.3% 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • 15.7% vs 7.9% 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • 20.3% vs 7.9% 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • 73.5% vs 61.7% 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • 72% vs 61.7% 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • 67.9% vs 68.3% 100 mg q8w · wk 52 · n 123 · Phase 3 · secondary NCT03162796
  • 75.8% vs 68.3% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 58% vs 18.4% wk 24 · n 100 · Phase 2 · primary NCT02319759
  • 60% vs 16.3% wk 16 · n 100 · Phase 2 · secondary NCT02319759
0.8% vs 0.5%+0.3 vs placeboI · wk 24 · n 78NCT02980692
3 other results
  • 0.8% vs 0.5% II · wk 24 · n 79 · Phase 2 · primary NCT02980692
  • 0.7% vs 0.5% Dose III · wk 24 · n 77 · Phase 2 · primary NCT02980692
  • 0.7% vs 0.5% Dose IV · wk 24 · n 78 · Phase 2 · primary NCT02980692
ACR5043.4% vs 36.5%+6.9 vs placebo100 mg q8w · wk 52 · n 123NCT03162796
26 other results
  • 55.6% vs 36.5% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 51.3% vs 30.8% 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • 46% vs 30.8% 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • 47.1% vs 32.7% 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • 44.6% vs 32.7% 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • 42.6% vs 21.4% 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • 39.2% vs 21.4% 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • 29.9% vs 8.7% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 35.9% vs 8.7% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 29.9% vs 8.7% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 35.9% vs 8.7% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 30.9% vs 9.6% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 36.8% vs 9.6% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 29.1% vs 13.5% 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • 37.5% vs 13.5% 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • 22.8% vs 12.7% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 26.6% vs 12.7% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 22.8% vs 12.7% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 26.6% vs 12.7% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 20.5% vs 10.3% 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • 24.2% vs 10.3% 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • 7.9% vs 7.9% 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • 10.9% vs 7.9% 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • 1.6% vs 2.4% 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • 3.1% vs 2.4% 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • 34% vs 10.2% wk 24 · n 100 · Phase 2 · secondary NCT02319759
—Not posted · NCT04314544
PASI 7580% vs 84.8%−4.8 vs placebo100 mg q8w · wk 52 · n 82NCT03162796
8 other results
  • 94.3% vs 84.8% 100 mg q4w · wk 52 · n 88 · Phase 3 · secondary NCT03162796
  • 75.6% vs 14.1% 100 mg q8w · wk 24 · n 82 · Phase 3 · secondary NCT03162796
  • 86.5% vs 14.1% 100 mg q4w · wk 24 · n 89 · Phase 3 · secondary NCT03162796
  • 76.5% vs 20.6% 100 mg q8w · wk 24 · n 82 · Phase 3 · secondary NCT03162796
  • 87.5% vs 20.6% 100 mg q4w · wk 24 · n 88 · Phase 3 · secondary NCT03162796
  • 63.4% vs 20.5% 100 mg q8w · wk 16 · n 82 · Phase 3 · secondary NCT03162796
  • 73% vs 20.5% 100 mg q4w · wk 16 · n 89 · Phase 3 · secondary NCT03162796
  • 78.6% vs 12.5% wk 24 · n 98 · Phase 2 · secondary NCT02319759
—Not posted · NCT04314544
Minimal disease activity33.9% vs 31.1%+2.8 vs placebo100 mg q8w · wk 52 · n 123NCT03162796
9 other results
  • 40.3% vs 31.1% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 22.8% vs 11.1% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 30.5% vs 11.1% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 23.6% vs 12.3% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 31.2% vs 12.3% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 15.7% vs 7.1% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 18% vs 7.1% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 23% vs 2% wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • 18% vs 0% wk 16 · n 100 · Phase 2 · secondary NCT02319759
—Not posted · NCT04314544
HAQ-DI, change-0.4 vs -0.4−0.1 vs placebo100 mg q8w · wk 52 · n 123NCT03162796
30 other results
  • -0.5 vs -0.4 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • -0.5 vs -0.4 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.4 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.3 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.3 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.2 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.2 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • -0.1 vs 0.0 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • -0.1 vs 0.0 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 20 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 16 · n 100 · Phase 2 · secondary NCT02319759
  • -0.3 vs -0.1 wk 12 · n 100 · Phase 2 · secondary NCT02319759
  • -0.3 vs -0.1 wk 8 · n 100 · Phase 2 · secondary NCT02319759
  • -0.2 vs -0.0 wk 4 · n 100 · Phase 2 · secondary NCT02319759
—Not posted · NCT04314544

ACR20

guselkumab
52% vs 22.2%+29.8 vs placebo100 mg q8w · wk 24 · n 127NCT03162796
27 other results
  • 59.4% vs 22.2% 100 mg q4w · wk 24 · n 128 · Phase 3 · primary NCT03162796
  • 52% vs 22.2% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 59.4% vs 22.2% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 54.5% vs 27.2% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 60.8% vs 27.2% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 51.2% vs 30.2% 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • 62.5% vs 30.2% 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • 68.9% vs 50% 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • 74.4% vs 50% 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • 52% vs 25.4% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 60.2% vs 25.4% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 52% vs 25.4% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 60.2% vs 25.4% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 43.3% vs 27% 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • 53.1% vs 27% 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • 70.3% vs 56.9% 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • 71.1% vs 56.9% 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • 36.2% vs 18.3% 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • 39.1% vs 18.3% 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • 15.7% vs 7.9% 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • 20.3% vs 7.9% 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • 73.5% vs 61.7% 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • 72% vs 61.7% 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • 67.9% vs 68.3% 100 mg q8w · wk 52 · n 123 · Phase 3 · secondary NCT03162796
  • 75.8% vs 68.3% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 58% vs 18.4% wk 24 · n 100 · Phase 2 · primary NCT02319759
  • 60% vs 16.3% wk 16 · n 100 · Phase 2 · secondary NCT02319759
tildrakizumab
0.8% vs 0.5%+0.3 vs placeboI · wk 24 · n 78NCT02980692
3 other results
  • 0.8% vs 0.5% II · wk 24 · n 79 · Phase 2 · primary NCT02980692
  • 0.7% vs 0.5% Dose III · wk 24 · n 77 · Phase 2 · primary NCT02980692
  • 0.7% vs 0.5% Dose IV · wk 24 · n 78 · Phase 2 · primary NCT02980692

ACR50

guselkumab
43.4% vs 36.5%+6.9 vs placebo100 mg q8w · wk 52 · n 123NCT03162796
26 other results
  • 55.6% vs 36.5% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 51.3% vs 30.8% 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • 46% vs 30.8% 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • 47.1% vs 32.7% 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • 44.6% vs 32.7% 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • 42.6% vs 21.4% 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • 39.2% vs 21.4% 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • 29.9% vs 8.7% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 35.9% vs 8.7% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 29.9% vs 8.7% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 35.9% vs 8.7% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 30.9% vs 9.6% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 36.8% vs 9.6% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 29.1% vs 13.5% 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • 37.5% vs 13.5% 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • 22.8% vs 12.7% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 26.6% vs 12.7% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 22.8% vs 12.7% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 26.6% vs 12.7% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 20.5% vs 10.3% 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • 24.2% vs 10.3% 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • 7.9% vs 7.9% 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • 10.9% vs 7.9% 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • 1.6% vs 2.4% 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • 3.1% vs 2.4% 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • 34% vs 10.2% wk 24 · n 100 · Phase 2 · secondary NCT02319759
tildrakizumab
—Not posted · NCT04314544

PASI 75

guselkumab
80% vs 84.8%−4.8 vs placebo100 mg q8w · wk 52 · n 82NCT03162796
8 other results
  • 94.3% vs 84.8% 100 mg q4w · wk 52 · n 88 · Phase 3 · secondary NCT03162796
  • 75.6% vs 14.1% 100 mg q8w · wk 24 · n 82 · Phase 3 · secondary NCT03162796
  • 86.5% vs 14.1% 100 mg q4w · wk 24 · n 89 · Phase 3 · secondary NCT03162796
  • 76.5% vs 20.6% 100 mg q8w · wk 24 · n 82 · Phase 3 · secondary NCT03162796
  • 87.5% vs 20.6% 100 mg q4w · wk 24 · n 88 · Phase 3 · secondary NCT03162796
  • 63.4% vs 20.5% 100 mg q8w · wk 16 · n 82 · Phase 3 · secondary NCT03162796
  • 73% vs 20.5% 100 mg q4w · wk 16 · n 89 · Phase 3 · secondary NCT03162796
  • 78.6% vs 12.5% wk 24 · n 98 · Phase 2 · secondary NCT02319759
tildrakizumab
—Not posted · NCT04314544

Minimal disease activity

guselkumab
33.9% vs 31.1%+2.8 vs placebo100 mg q8w · wk 52 · n 123NCT03162796
9 other results
  • 40.3% vs 31.1% 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • 22.8% vs 11.1% 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • 30.5% vs 11.1% 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • 23.6% vs 12.3% 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • 31.2% vs 12.3% 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • 15.7% vs 7.1% 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • 18% vs 7.1% 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • 23% vs 2% wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • 18% vs 0% wk 16 · n 100 · Phase 2 · secondary NCT02319759
tildrakizumab
—Not posted · NCT04314544

HAQ-DI, change

guselkumab
-0.4 vs -0.4−0.1 vs placebo100 mg q8w · wk 52 · n 123NCT03162796
30 other results
  • -0.5 vs -0.4 100 mg q4w · wk 52 · n 125 · Phase 3 · secondary NCT03162796
  • -0.5 vs -0.4 100 mg q8w · wk 44 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.4 100 mg q4w · wk 44 · n 125 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.3 100 mg q8w · wk 36 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.3 100 mg q4w · wk 36 · n 125 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.2 100 mg q8w · wk 28 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.2 100 mg q4w · wk 28 · n 125 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 24 · n 123 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 24 · n 125 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 20 · n 127 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 100 mg q4w · wk 20 · n 128 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q8w · wk 16 · n 127 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q4w · wk 16 · n 128 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q8w · wk 12 · n 127 · Phase 3 · secondary NCT03162796
  • -0.3 vs -0.1 100 mg q4w · wk 12 · n 128 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q8w · wk 8 · n 127 · Phase 3 · secondary NCT03162796
  • -0.2 vs -0.1 100 mg q4w · wk 8 · n 128 · Phase 3 · secondary NCT03162796
  • -0.1 vs 0.0 100 mg q8w · wk 4 · n 127 · Phase 3 · secondary NCT03162796
  • -0.1 vs 0.0 100 mg q4w · wk 4 · n 128 · Phase 3 · secondary NCT03162796
  • -0.4 vs -0.1 wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 24 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 20 · n 100 · Phase 2 · secondary NCT02319759
  • -0.4 vs -0.1 wk 16 · n 100 · Phase 2 · secondary NCT02319759
  • -0.3 vs -0.1 wk 12 · n 100 · Phase 2 · secondary NCT02319759
  • -0.3 vs -0.1 wk 8 · n 100 · Phase 2 · secondary NCT02319759
  • -0.2 vs -0.0 wk 4 · n 100 · Phase 2 · secondary NCT02319759
tildrakizumab
—Not posted · NCT04314544
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. guselkumab: 14 of 14 rows · tildrakizumab: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumab
Rows use multiple source trials
tildrakizumab
ACR20
responder rate · % of participants
No placebo or comparator arm
75.9% (n=234) @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
77% (n=227) @ 52wk100 mg q4w
NCT03158285 · Phase 3
79.1% (n=240) @ 52wk100 mg q8w
NCT03158285 · Phase 3
78.9% (n=232) @ 52wk100 mg q8w
NCT03158285 · Phase 3
0.8667% (n=60) @ 52wkDose IIIa,b,c,d
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
0.8133% (n=75) @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.9254% (n=67) @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.8906% (n=64) @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
ACR50
responder rate · % of participants
No placebo or comparator arm
49.1% (n=234) @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
49.6% (n=227) @ 52wk100 mg q4w
NCT03158285 · Phase 3
51.3% (n=240) @ 52wk100 mg q8w
NCT03158285 · Phase 3
50.9% (n=232) @ 52wk100 mg q8w
NCT03158285 · Phase 3
0.7213% (n=77) @ 52wkDose IIIa,b,c,d
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
0.68% (n=78) @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.791% (n=78) @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.75% (n=79) @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
ACR70
responder rate · % of participants
No placebo or comparator arm
28.1% (n=234) @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
28.3% (n=227) @ 52wk100 mg q4w
NCT03158285 · Phase 3
29.5% (n=240) @ 52wk100 mg q8w
NCT03158285 · Phase 3
29.7% (n=232) @ 52wk100 mg q8w
NCT03158285 · Phase 3
0.3934% (n=77) @ 52wkDose IIIa,b,c,d
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
0.4% (n=78) @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.5821% (n=78) @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.4844% (n=79) @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
Dactylitis
absolute change · score
-5.82 vs -4.3 placebo score @ 24wk100 mg q4wa,b,c,d
NCT03162796 · Phase 3
show 5 more doses
-5.82 vs -4.3 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-6.6 vs -4 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-6.11 vs -4.3 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-6.11 vs -4.3 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-6.2 vs -4 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-27.572 vs -24.706 placebo score @ 24wkDose IIIa,b,c,d
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
-19.873 vs -24.706 placebo score @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-22.987 vs -24.706 placebo score @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-25.123 vs -24.706 placebo score @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
Dactylitis
absolute change · score
No placebo or comparator arm
-7.4 score @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
-7.4 score @ 52wk100 mg q4w
NCT03158285 · Phase 3
-7.3 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
-7.3 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
-27.084 score @ 52wkDose IIIa,b,c,d
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
-26.173 score @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
-14.453 score @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-18.883 score @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
DAS28 (CRP
responder rate · % of participants
No placebo or comparator arm
89.4% (n=234) @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
90.2% (n=227) @ 52wk100 mg q4w
NCT03158285 · Phase 3
89.7% (n=240) @ 52wk100 mg q8w
NCT03158285 · Phase 3
89.7% (n=232) @ 52wk100 mg q8w
NCT03158285 · Phase 3
76.27% (n=77) @ 52wkDose IIIa,b,c,d
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
71.05% (n=78) @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
85.07% (n=78) @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
81.25% (n=79) @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
Enthesitis
absolute change · score
-1.75 vs -1.01 placebo score @ 24wk100 mg q4wa,b,c,d
NCT03162796 · Phase 3
show 1 more dose
-1.35 vs -1.01 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-1.2 vs -0.8 placebo score @ 24wkDose IIIa,b,c,d
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
-1.1 vs -0.8 placebo score @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-1.3 vs -0.8 placebo score @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.9 vs -0.8 placebo score @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
Enthesitis
absolute change · score
No placebo or comparator arm
-2 score @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
-2.1 score @ 52wk100 mg q4w
NCT03158285 · Phase 3
-1.9 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
-1.9 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
-1.7 score @ 52wkDose IIIa,b,c,d
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
-1.2 score @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
-1.3 score @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-1 score @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
HAQ-DI
absolute change · score
No placebo or comparator arm
-0.5082 score @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
-0.5111 score @ 52wk100 mg q4w
NCT03158285 · Phase 3
-0.4824 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
-0.4801 score @ 52wk100 mg q8w
NCT03158285 · Phase 3
-0.4857 score @ 52wkDose IIIa,b,c,d
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
-0.4583 score @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.4869 score @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.543 score @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
MDA
responder rate · % of participants
No placebo or comparator arm
36.8% (n=234) @ 52wk100 mg q4wa,b,c,d
NCT03158285 · Phase 3
show 3 more doses
37.2% (n=227) @ 52wk100 mg q4w
NCT03158285 · Phase 3
32.9% (n=240) @ 52wk100 mg q8w
NCT03158285 · Phase 3
32.8% (n=232) @ 52wk100 mg q8w
NCT03158285 · Phase 3
45% (n=77) @ 52wkDose IIIa,b,c,d
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
47.06% (n=78) @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
56.92% (n=78) @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
64.41% (n=79) @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
Dropout rate
2.3%100 mg q4we
NCT03162796 · Phase 3
show 13 more results
—100 mg q4w
NCT03162796 · Phase 3
—100 mg q4w
NCT03162796 · Phase 3
3.1%100 mg q8w
NCT03162796 · Phase 3
—100 mg q8w
NCT03162796 · Phase 3
—100 mg q8w
NCT03162796 · Phase 3
3.7%100 mg q4w
NCT03158285 · Phase 3
—100 mg q4w
NCT03158285 · Phase 3
—100 mg q4w
NCT03158285 · Phase 3
3.2%100 mg q8w
NCT03158285 · Phase 3
—100 mg q8w
NCT03158285 · Phase 3
—100 mg q8w
NCT03158285 · Phase 3
1%Guselkumab (Week 0 to Week 56)
NCT02319759 · Phase 2 · registry result, not featured evidence
—Placebo to Guselkumab (Week 24 to
NCT02319759 · Phase 2 · registry result, not featured evidence
100%200 mg q12 Weekse
NCT03552276 · Phase 2/3 · registry result, not featured evidence
show 23 more results
16.6%200 mg q12 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q12 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
100%200 mg q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
14.8%200 mg q4 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg, q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg, q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
32.7%100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
22.1%Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
9%Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
20.5%I
NCT02980692 · Phase 2 · registry result, not featured evidence
19%II
NCT02980692 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.8%100 mg q4we
NCT03162796 · Phase 3
show 13 more results
—100 mg q4w
NCT03162796 · Phase 3
—100 mg q4w
NCT03162796 · Phase 3
2.4%100 mg q8w
NCT03162796 · Phase 3
—100 mg q8w
NCT03162796 · Phase 3
—100 mg q8w
NCT03162796 · Phase 3
2.4%100 mg q4w
NCT03158285 · Phase 3
—100 mg q4w
NCT03158285 · Phase 3
—100 mg q4w
NCT03158285 · Phase 3
0.8%100 mg q8w
NCT03158285 · Phase 3
—100 mg q8w
NCT03158285 · Phase 3
—100 mg q8w
NCT03158285 · Phase 3
—Guselkumab (Week 0 to Week 56)
NCT02319759 · Phase 2 · registry result, not featured evidence
—Placebo to Guselkumab (Week 24 to
NCT02319759 · Phase 2 · registry result, not featured evidence
—200 mg q12 Weekse
NCT03552276 · Phase 2/3 · registry result, not featured evidence
show 23 more results
—200 mg q12 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q12 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg, q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg, q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
1.3%Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
2.6%Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
1.3%I
NCT02980692 · Phase 2 · registry result, not featured evidence
2.5%II
NCT02980692 · Phase 2 · registry result, not featured evidence
Serious AEs
—100 mg q4we
NCT03162796 · Phase 3
show 13 more results
0%100 mg q4w
NCT03162796 · Phase 3
3.1%100 mg q4w
NCT03162796 · Phase 3
—100 mg q8w
NCT03162796 · Phase 3
3.1%100 mg q8w
NCT03162796 · Phase 3
6.3%100 mg q8w
NCT03162796 · Phase 3
—100 mg q4w
NCT03158285 · Phase 3
3.3%100 mg q4w
NCT03158285 · Phase 3
9%100 mg q4w
NCT03158285 · Phase 3
—100 mg q8w
NCT03158285 · Phase 3
1.2%100 mg q8w
NCT03158285 · Phase 3
8.9%100 mg q8w
NCT03158285 · Phase 3
6%Guselkumab (Week 0 to Week 56)
NCT02319759 · Phase 2 · registry result, not featured evidence
0%Placebo to Guselkumab (Week 24 to
NCT02319759 · Phase 2 · registry result, not featured evidence
—200 mg q12 Weekse
NCT03552276 · Phase 2/3 · registry result, not featured evidence
show 23 more results
—200 mg q12 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
16.6%200 mg q12 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
5.6%200 mg q4 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
9.1%200 mg, q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
60%200 mg, q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
14.3%100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
2.6%Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
1.3%Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
2.5%II
NCT02980692 · Phase 2 · registry result, not featured evidence
2.6%I
NCT02980692 · Phase 2 · registry result, not featured evidence
0%Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0%II
NCT02980692 · Phase 2 · registry result, not featured evidence
0%I
NCT02980692 · Phase 2 · registry result, not featured evidence
3.8%Dose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
1.3%Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
1.3%II
NCT02980692 · Phase 2 · registry result, not featured evidence
3.8%I
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mg q4we
upper respiratory tract infection 8.6% (placebo 6.3%)
nasopharyngitis 5.5% (placebo 6.3%)
enthesopathy 4.7% (placebo 4.8%)
NCT03162796 · Phase 3
show 9 more results
100 mg q4w
upper respiratory tract infection 12.5% (placebo 6.3%)
nasopharyngitis 10.9% (placebo 6.3%)
alanine aminotransferase increased 7% (placebo 2.4%)
NCT03162796 · Phase 3
100 mg q8w
nasopharyngitis 12.6% (placebo 6.3%)
aspartate aminotransferase increased 7.1% (placebo 2.4%)
alanine aminotransferase increased 6.3% (placebo 2.4%)
NCT03162796 · Phase 3
100 mg q8w
nasopharyngitis 16.5% (placebo 6.3%)
aspartate aminotransferase increased 8.7% (placebo 2.4%)
upper respiratory tract infection 7.9% (placebo 6.3%)
NCT03162796 · Phase 3
100 mg q4w
alanine aminotransferase increased 9% (placebo 4.5%)
upper respiratory tract infection 5.3% (placebo 3.3%)
nasopharyngitis 4.9% (placebo 3.7%)
NCT03158285 · Phase 3
100 mg q4w
alanine aminotransferase increased 12.7% (placebo 4.5%)
aspartate aminotransferase increased 9.4% (placebo 2.4%)
nasopharyngitis 8.6% (placebo 3.7%)
NCT03158285 · Phase 3
100 mg q8w
alanine aminotransferase increased 6% (placebo 4.5%)
aspartate aminotransferase increased 5.6% (placebo 2.4%)
nasopharyngitis 4% (placebo 3.7%)
NCT03158285 · Phase 3
100 mg q8w
alanine aminotransferase increased 11.7% (placebo 4.5%)
nasopharyngitis 10.1% (placebo 3.7%)
upper respiratory tract infection 9.7% (placebo 3.3%)
NCT03158285 · Phase 3
nasopharyngitis 10% (placebo 10.2%)
leukopenia 5% (placebo 0%)
alanine aminotransferase increased 4% (placebo 2%)
NCT02319759 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 6.9% (placebo 2%)
aspartate aminotransferase increased 6.9% (placebo 0%)
leukopenia 3.4% (placebo 0%)
NCT02319759 · Phase 2 · registry result, not featured evidence
200 mg q12 Weeks, to 100 mg q12 Weekse
covid-19 16.6%
nasopharyngitis 13.9%
urinary tract infection 11.9%
NCT03552276 · Phase 2/3 · registry result, not featured evidence
show 15 more results
200 mg q4 Weeks, to 100 mg q12 Weeks
covid-19 20.4%
upper respiratory tract infection 16.7%
nasopharyngitis 14.8%
NCT03552276 · Phase 2/3 · registry result, not featured evidence
200 mg, q12 Weeks
diarrhoea 18.2%
arthralgia 13.6%
arthritis 9.1%
NCT03552276 · Phase 2/3 · registry result, not featured evidence
200 mg, q4 Weeks
hypertension 40%
abdominal abscess 20%
alanine aminotransferase increased 20%
NCT03552276 · Phase 2/3 · registry result, not featured evidence
100 mg q12 Weeks
nasopharyngitis 14.3%
upper respiratory tract infection 14.3%
abdominal pain 8.2%
NCT03552276 · Phase 2/3 · registry result, not featured evidence
Dose III
headache 6.5% (placebo 3.8%)
nasopharyngitis 5.2% (placebo 6.3%)
upper respiratory tract infection 3.9% (placebo 1.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
Dose IV
diarrhoea 6.4% (placebo 0%)
headache 6.4% (placebo 3.8%)
nasopharyngitis 6.4% (placebo 6.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
II
hypertension 7.6% (placebo 6.3%)
sleep disorder 6.3% (placebo 1.3%)
upper respiratory tract infection 5.1% (placebo 1.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
I
nasopharyngitis 9% (placebo 6.3%)
headache 5.1% (placebo 3.8%)
hypertension 3.8% (placebo 6.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
Dose III
headache 2.6% (placebo 3.8%)
nasopharyngitis 2.6% (placebo 6.3%)
upper respiratory tract infection 2.6% (placebo 1.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
II
upper respiratory tract infection 5.1% (placebo 1.3%)
headache 3.8% (placebo 3.8%)
nasopharyngitis 2.5% (placebo 6.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
I
hypertension 5.1% (placebo 6.3%)
upper respiratory tract infection 3.8% (placebo 1.3%)
aspartate aminotransferase increased 2.6% (placebo 0%)
NCT02980692 · Phase 2 · registry result, not featured evidence
Dose IV then SUNPG1623 II
nasopharyngitis 9% (placebo 6.3%)
upper respiratory tract infection 5.1% (placebo 1.3%)
urinary tract infection 5.1% (placebo 3.8%)
NCT02980692 · Phase 2 · registry result, not featured evidence
Dose III
headache 1.3% (placebo 3.8%)
nasopharyngitis 1.3% (placebo 6.3%)
upper respiratory tract infection 1.3% (placebo 1.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
II
aspartate aminotransferase increased 1.3% (placebo 0%)
diarrhoea 0% (placebo 0%)
headache 0% (placebo 3.8%)
NCT02980692 · Phase 2 · registry result, not featured evidence
I
headache 3.8% (placebo 3.8%)
aspartate aminotransferase increased 2.6% (placebo 0%)
nasopharyngitis 2.6% (placebo 6.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

HAQ-DI -0.3225 vs -0.0743 placebo score @ 24wk100 mg q8w
absolute change · score
NCT03162796 · Phase 3
show 30 more results
-0.3968 vs -0.0743 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-0.0571 vs 0.0043 placebo score @ 4wk100 mg q8w
NCT03162796 · Phase 3
-0.1095 vs 0.0043 placebo score @ 4wk100 mg q4w
NCT03162796 · Phase 3
-0.1711 vs -0.0781 placebo score @ 8wk100 mg q8w
NCT03162796 · Phase 3
-0.1907 vs -0.0781 placebo score @ 8wk100 mg q4w
NCT03162796 · Phase 3
-0.2174 vs -0.1013 placebo score @ 12wk100 mg q8w
NCT03162796 · Phase 3
-0.3209 vs -0.1013 placebo score @ 12wk100 mg q4w
NCT03162796 · Phase 3
-0.262 vs -0.1131 placebo score @ 16wk100 mg q8w
NCT03162796 · Phase 3
-0.3393 vs -0.1131 placebo score @ 16wk100 mg q4w
NCT03162796 · Phase 3
-0.3293 vs -0.1079 placebo score @ 20wk100 mg q8w
NCT03162796 · Phase 3
-0.3708 vs -0.1079 placebo score @ 20wk100 mg q4w
NCT03162796 · Phase 3
-0.3225 vs -0.0743 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-0.3968 vs -0.0743 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-0.3374 vs -0.1217 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-0.374 vs -0.1217 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-0.4004 vs -0.2241 placebo score @ 28wk100 mg q8w
NCT03162796 · Phase 3
-0.385 vs -0.2241 placebo score @ 28wk100 mg q4w
NCT03162796 · Phase 3
-0.4396 vs -0.2602 placebo score @ 36wk100 mg q8w
NCT03162796 · Phase 3
-0.4132 vs -0.2602 placebo score @ 36wk100 mg q4w
NCT03162796 · Phase 3
-0.4672 vs -0.3634 placebo score @ 44wk100 mg q8w
NCT03162796 · Phase 3
-0.418 vs -0.3634 placebo score @ 44wk100 mg q4w
NCT03162796 · Phase 3
-0.4364 vs -0.3642 placebo score @ 52wk100 mg q8w
NCT03162796 · Phase 3
-0.497 vs -0.3642 placebo score @ 52wk100 mg q4w
NCT03162796 · Phase 3
-0.42 vs -0.06 placebo score @ 24wk
NCT02319759 · Phase 2 · registry result, not featured evidence
-0.17 vs -0.02 placebo score @ 4wk
NCT02319759 · Phase 2 · registry result, not featured evidence
-0.32 vs -0.07 placebo score @ 8wk
NCT02319759 · Phase 2 · registry result, not featured evidence
-0.33 vs -0.05 placebo score @ 12wk
NCT02319759 · Phase 2 · registry result, not featured evidence
-0.38 vs -0.05 placebo score @ 16wk
NCT02319759 · Phase 2 · registry result, not featured evidence
-0.41 vs -0.08 placebo score @ 20wk
NCT02319759 · Phase 2 · registry result, not featured evidence
-0.42 vs -0.06 placebo score @ 24wk
NCT02319759 · Phase 2 · registry result, not featured evidence
ACR50 29.9% (n=127) vs 8.7% (n=126) placebo @ 24wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 26 more results
35.9% (n=128) vs 8.7% (n=126) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
22.8% (n=127) vs 12.7% (n=126) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
26.6% (n=128) vs 12.7% (n=126) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
1.6% (n=127) vs 2.4% (n=126) placebo @ 4wk100 mg q8w
NCT03162796 · Phase 3
3.1% (n=128) vs 2.4% (n=126) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
7.9% (n=127) vs 7.9% (n=126) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
10.9% (n=128) vs 7.9% (n=126) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
20.5% (n=127) vs 10.3% (n=126) placebo @ 12wk100 mg q8w
NCT03162796 · Phase 3
24.2% (n=128) vs 10.3% (n=126) placebo @ 12wk100 mg q4w
NCT03162796 · Phase 3
22.8% (n=127) vs 12.7% (n=126) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
26.6% (n=128) vs 12.7% (n=126) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
29.1% (n=127) vs 13.5% (n=126) placebo @ 20wk100 mg q8w
NCT03162796 · Phase 3
37.5% (n=128) vs 13.5% (n=126) placebo @ 20wk100 mg q4w
NCT03162796 · Phase 3
29.9% (n=127) vs 8.7% (n=126) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
35.9% (n=128) vs 8.7% (n=126) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
30.9% (n=123) vs 9.6% (n=114) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
36.8% (n=125) vs 9.6% (n=114) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
42.6% (n=123) vs 21.4% (n=114) placebo @ 28wk100 mg q8w
NCT03162796 · Phase 3
39.2% (n=125) vs 21.4% (n=114) placebo @ 28wk100 mg q4w
NCT03162796 · Phase 3
47.1% (n=123) vs 32.7% (n=114) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
44.6% (n=125) vs 32.7% (n=114) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
51.3% (n=123) vs 30.8% (n=114) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
46% (n=125) vs 30.8% (n=114) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
43.4% (n=123) vs 36.5% (n=114) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
55.6% (n=125) vs 36.5% (n=114) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
34% (n=100) vs 10.2% (n=49) placebo @ 24wk
NCT02319759 · Phase 2 · registry result, not featured evidence
IGA 0/1 57.3% (n=82) vs 15.4% (n=78) placebo @ 24wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 5 more results
75.3% (n=89) vs 15.4% (n=78) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
38.3% (n=82) vs 8.8% (n=68) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
54.5% (n=88) vs 8.8% (n=68) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
53.3% (n=82) vs 66.2% (n=68) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
67% (n=88) vs 66.2% (n=68) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
DAS28-CRP -1.43 vs -0.7 placebo score @ 24wk100 mg q8w
absolute change · score
NCT03162796 · Phase 3
show 23 more results
-1.61 vs -0.7 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-0.53 vs -0.35 placebo score @ 4wk100 mg q8w
NCT03162796 · Phase 3
-0.56 vs -0.35 placebo score @ 4wk100 mg q4w
NCT03162796 · Phase 3
-0.83 vs -0.55 placebo score @ 8wk100 mg q8w
NCT03162796 · Phase 3
-0.88 vs -0.55 placebo score @ 8wk100 mg q4w
NCT03162796 · Phase 3
-1.16 vs -0.63 placebo score @ 12wk100 mg q8w
NCT03162796 · Phase 3
-1.23 vs -0.63 placebo score @ 12wk100 mg q4w
NCT03162796 · Phase 3
-1.19 vs -0.64 placebo score @ 16wk100 mg q8w
NCT03162796 · Phase 3
-1.38 vs -0.64 placebo score @ 16wk100 mg q4w
NCT03162796 · Phase 3
-1.38 vs -0.8 placebo score @ 20wk100 mg q8w
NCT03162796 · Phase 3
-1.56 vs -0.8 placebo score @ 20wk100 mg q4w
NCT03162796 · Phase 3
-1.43 vs -0.7 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-1.61 vs -0.7 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-1.49 vs -0.84 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-1.57 vs -0.84 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-1.71 vs -1.33 placebo score @ 28wk100 mg q8w
NCT03162796 · Phase 3
-1.67 vs -1.33 placebo score @ 28wk100 mg q4w
NCT03162796 · Phase 3
-1.96 vs -1.6 placebo score @ 36wk100 mg q8w
NCT03162796 · Phase 3
-1.78 vs -1.6 placebo score @ 36wk100 mg q4w
NCT03162796 · Phase 3
-1.96 vs -1.69 placebo score @ 44wk100 mg q8w
NCT03162796 · Phase 3
-1.92 vs -1.69 placebo score @ 44wk100 mg q4w
NCT03162796 · Phase 3
-2.03 vs -1.84 placebo score @ 52wk100 mg q8w
NCT03162796 · Phase 3
-1.99 vs -1.84 placebo score @ 52wk100 mg q4w
NCT03162796 · Phase 3
ACR70 11.8% (n=127) vs 5.6% (n=126) placebo @ 24wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 23 more results
20.3% (n=128) vs 5.6% (n=126) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
0.8% (n=127) vs 0% (n=126) placebo @ 4wk100 mg q8w
NCT03162796 · Phase 3
0% (n=128) vs 0% (n=126) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
3.1% (n=127) vs 1.6% (n=126) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
2.3% (n=128) vs 1.6% (n=126) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
7.1% (n=127) vs 4.8% (n=126) placebo @ 12wk100 mg q8w
NCT03162796 · Phase 3
6.3% (n=128) vs 4.8% (n=126) placebo @ 12wk100 mg q4w
NCT03162796 · Phase 3
7.9% (n=127) vs 5.6% (n=126) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
7.8% (n=128) vs 5.6% (n=126) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
11.8% (n=127) vs 7.1% (n=126) placebo @ 20wk100 mg q8w
NCT03162796 · Phase 3
17.2% (n=128) vs 7.1% (n=126) placebo @ 20wk100 mg q4w
NCT03162796 · Phase 3
11.8% (n=127) vs 5.6% (n=126) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
20.3% (n=128) vs 5.6% (n=126) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
12.2% (n=123) vs 6.1% (n=114) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
20.8% (n=125) vs 6.1% (n=114) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
20.5% (n=123) vs 9.8% (n=114) placebo @ 28wk100 mg q8w
NCT03162796 · Phase 3
24.8% (n=125) vs 9.8% (n=114) placebo @ 28wk100 mg q4w
NCT03162796 · Phase 3
25.2% (n=123) vs 18% (n=114) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
26.4% (n=125) vs 18% (n=114) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
28.4% (n=123) vs 16.8% (n=114) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
26.4% (n=125) vs 16.8% (n=114) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
28.9% (n=123) vs 19.2% (n=114) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
29.8% (n=125) vs 19.2% (n=114) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
SF-36 PCS 6.1 vs 1.96 placebo score @ 24wk100 mg q8w
absolute change · score
NCT03162796 · Phase 3
show 13 more results
6.87 vs 1.96 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
2.87 vs 2.15 placebo score @ 8wk100 mg q8w
NCT03162796 · Phase 3
4.46 vs 2.15 placebo score @ 8wk100 mg q4w
NCT03162796 · Phase 3
5.26 vs 2.5 placebo score @ 16wk100 mg q8w
NCT03162796 · Phase 3
6.72 vs 2.5 placebo score @ 16wk100 mg q4w
NCT03162796 · Phase 3
6.1 vs 1.96 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
6.87 vs 1.96 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
6.505 vs 2.7 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
6.56 vs 2.7 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
7.439 vs 5.456 placebo score @ 36wk100 mg q8w
NCT03162796 · Phase 3
7.162 vs 5.456 placebo score @ 36wk100 mg q4w
NCT03162796 · Phase 3
7.278 vs 6.905 placebo score @ 52wk100 mg q8w
NCT03162796 · Phase 3
8.517 vs 6.905 placebo score @ 52wk100 mg q4w
NCT03162796 · Phase 3
Enthesitis Resolution 40.3% (n=72) vs 27.3% (n=77) placebo @ 24wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 17 more results
47.9% (n=73) vs 27.3% (n=77) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
18.1% (n=72) vs 22.1% (n=77) placebo @ 4wk100 mg q8w
NCT03162796 · Phase 3
27.4% (n=73) vs 22.1% (n=77) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
30.6% (n=72) vs 23.4% (n=77) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
30.1% (n=73) vs 23.4% (n=77) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
34.7% (n=72) vs 37.7% (n=77) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
45.2% (n=73) vs 37.7% (n=77) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
40.3% (n=72) vs 27.3% (n=77) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
47.9% (n=73) vs 27.3% (n=77) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
40.8% (n=71) vs 31% (n=71) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
49.3% (n=71) vs 31% (n=71) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
52.9% (n=71) vs 49.3% (n=71) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
58% (n=71) vs 49.3% (n=71) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
46.4% (n=71) vs 58.2% (n=71) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
71.8% (n=71) vs 58.2% (n=71) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
56.3% (n=71) vs 69.8% (n=71) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
62.9% (n=71) vs 69.8% (n=71) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
Leeds Enthesitis Index -1.35 vs -1.01 placebo score @ 24wk100 mg q8w
absolute change · score
NCT03162796 · Phase 3
show 9 more results
-1.75 vs -1.01 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-1.2 vs -1 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
-1.8 vs -1 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
-1.3 vs -1.4 placebo score @ 36wk100 mg q8w
NCT03162796 · Phase 3
-2 vs -1.4 placebo score @ 36wk100 mg q4w
NCT03162796 · Phase 3
-1.6 vs -1.6 placebo score @ 44wk100 mg q8w
NCT03162796 · Phase 3
-2.4 vs -1.6 placebo score @ 44wk100 mg q4w
NCT03162796 · Phase 3
-1.8 vs -1.9 placebo score @ 52wk100 mg q8w
NCT03162796 · Phase 3
-2 vs -1.9 placebo score @ 52wk100 mg q4w
NCT03162796 · Phase 3
SF-36 MCS 3.2 vs 2.37 placebo score @ 24wk100 mg q8w
absolute change · score
NCT03162796 · Phase 3
show 13 more results
3.6 vs 2.37 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
2.72 vs 1.99 placebo score @ 8wk100 mg q8w
NCT03162796 · Phase 3
2.46 vs 1.99 placebo score @ 8wk100 mg q4w
NCT03162796 · Phase 3
2.61 vs 2.25 placebo score @ 16wk100 mg q8w
NCT03162796 · Phase 3
3.04 vs 2.25 placebo score @ 16wk100 mg q4w
NCT03162796 · Phase 3
3.2 vs 2.37 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
3.6 vs 2.37 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
3.027 vs 1.827 placebo score @ 24wk100 mg q8w
NCT03162796 · Phase 3
3.796 vs 1.827 placebo score @ 24wk100 mg q4w
NCT03162796 · Phase 3
4.3 vs 3.612 placebo score @ 36wk100 mg q8w
NCT03162796 · Phase 3
4.326 vs 3.612 placebo score @ 36wk100 mg q4w
NCT03162796 · Phase 3
5.139 vs 4.24 placebo score @ 52wk100 mg q8w
NCT03162796 · Phase 3
4.931 vs 4.24 placebo score @ 52wk100 mg q4w
NCT03162796 · Phase 3
Dactylitis Resolution 65.3% (n=49) vs 49.1% (n=55) placebo @ 24wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 17 more results
63.2% (n=38) vs 49.1% (n=55) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
34.7% (n=49) vs 41.8% (n=55) placebo @ 4wk100 mg q8w
NCT03162796 · Phase 3
31.6% (n=38) vs 41.8% (n=55) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
40.8% (n=49) vs 41.8% (n=55) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
44.7% (n=38) vs 41.8% (n=55) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
59.2% (n=49) vs 43.6% (n=55) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
57.9% (n=38) vs 43.6% (n=55) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
65.3% (n=49) vs 49.1% (n=55) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
63.2% (n=38) vs 49.1% (n=55) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
67.3% (n=49) vs 61.7% (n=47) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
64.9% (n=37) vs 61.7% (n=47) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
67.4% (n=49) vs 79.5% (n=47) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
82.9% (n=37) vs 79.5% (n=47) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
76.1% (n=49) vs 84.8% (n=47) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
83.8% (n=37) vs 84.8% (n=47) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
79.5% (n=49) vs 81.4% (n=47) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
78.4% (n=37) vs 81.4% (n=47) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
HAQ-DI 26.8% (n=112) vs 20% (n=110) placebo @ 4wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 27 more results
30.9% (n=110) vs 20% (n=110) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
40.2% (n=112) vs 25.5% (n=110) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
38.2% (n=110) vs 25.5% (n=110) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
45.5% (n=112) vs 27.3% (n=110) placebo @ 12wk100 mg q8w
NCT03162796 · Phase 3
51.8% (n=110) vs 27.3% (n=110) placebo @ 12wk100 mg q4w
NCT03162796 · Phase 3
46.4% (n=112) vs 30.9% (n=110) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
57.3% (n=110) vs 30.9% (n=110) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
50.9% (n=112) vs 28.2% (n=110) placebo @ 20wk100 mg q8w
NCT03162796 · Phase 3
56.4% (n=110) vs 28.2% (n=110) placebo @ 20wk100 mg q4w
NCT03162796 · Phase 3
50.9% (n=112) vs 29.1% (n=110) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
57.3% (n=110) vs 29.1% (n=110) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
53.2% (n=109) vs 36% (n=100) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
57.8% (n=109) vs 36% (n=100) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
61.5% (n=109) vs 40.2% (n=100) placebo @ 28wk100 mg q8w
NCT03162796 · Phase 3
61.5% (n=109) vs 40.2% (n=100) placebo @ 28wk100 mg q4w
NCT03162796 · Phase 3
60.4% (n=109) vs 41.7% (n=100) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
61.9% (n=109) vs 41.7% (n=100) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
58.7% (n=109) vs 50% (n=100) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
62.4% (n=109) vs 50% (n=100) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
57.4% (n=109) vs 54.3% (n=100) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
68.5% (n=109) vs 54.3% (n=100) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3
29% (n=100) vs 12.2% (n=49) placebo @ 4wk
NCT02319759 · Phase 2 · registry result, not featured evidence
43% (n=100) vs 26.5% (n=49) placebo @ 8wk
NCT02319759 · Phase 2 · registry result, not featured evidence
47% (n=100) vs 22.4% (n=49) placebo @ 12wk
NCT02319759 · Phase 2 · registry result, not featured evidence
50% (n=100) vs 20.4% (n=49) placebo @ 16wk
NCT02319759 · Phase 2 · registry result, not featured evidence
48% (n=100) vs 22.4% (n=49) placebo @ 20wk
NCT02319759 · Phase 2 · registry result, not featured evidence
51% (n=100) vs 28.6% (n=49) placebo @ 24wk
NCT02319759 · Phase 2 · registry result, not featured evidence
DAS28 (CRP 33.1% (n=127) vs 27% (n=126) placebo @ 4wk100 mg q8w
responder rate · % of participants
NCT03162796 · Phase 3
show 21 more results
40.6% (n=128) vs 27% (n=126) placebo @ 4wk100 mg q4w
NCT03162796 · Phase 3
59.1% (n=127) vs 35.7% (n=126) placebo @ 8wk100 mg q8w
NCT03162796 · Phase 3
54.7% (n=128) vs 35.7% (n=126) placebo @ 8wk100 mg q4w
NCT03162796 · Phase 3
67.7% (n=127) vs 41.3% (n=126) placebo @ 12wk100 mg q8w
NCT03162796 · Phase 3
74.2% (n=128) vs 41.3% (n=126) placebo @ 12wk100 mg q4w
NCT03162796 · Phase 3
65.4% (n=127) vs 44.4% (n=126) placebo @ 16wk100 mg q8w
NCT03162796 · Phase 3
73.4% (n=128) vs 44.4% (n=126) placebo @ 16wk100 mg q4w
NCT03162796 · Phase 3
66.1% (n=127) vs 46% (n=126) placebo @ 20wk100 mg q8w
NCT03162796 · Phase 3
75% (n=128) vs 46% (n=126) placebo @ 20wk100 mg q4w
NCT03162796 · Phase 3
70.9% (n=127) vs 44.4% (n=126) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
76.6% (n=128) vs 44.4% (n=126) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
74.6% (n=123) vs 51.8% (n=114) placebo @ 24wk100 mg q8w
NCT03162796 · Phase 3
78.4% (n=125) vs 51.8% (n=114) placebo @ 24wk100 mg q4w
NCT03162796 · Phase 3
83.3% (n=123) vs 73.6% (n=114) placebo @ 28wk100 mg q8w
NCT03162796 · Phase 3
83.9% (n=125) vs 73.6% (n=114) placebo @ 28wk100 mg q4w
NCT03162796 · Phase 3
89% (n=123) vs 76.4% (n=114) placebo @ 36wk100 mg q8w
NCT03162796 · Phase 3
86.8% (n=125) vs 76.4% (n=114) placebo @ 36wk100 mg q4w
NCT03162796 · Phase 3
86.8% (n=123) vs 80% (n=114) placebo @ 44wk100 mg q8w
NCT03162796 · Phase 3
89.5% (n=125) vs 80% (n=114) placebo @ 44wk100 mg q4w
NCT03162796 · Phase 3
88.4% (n=123) vs 86.4% (n=114) placebo @ 52wk100 mg q8w
NCT03162796 · Phase 3
87.8% (n=125) vs 86.4% (n=114) placebo @ 52wk100 mg q4w
NCT03162796 · Phase 3

+ 80 further endpoints in the CSV export.

tildrakizumab

Tender Joint Count -1.5 vs -2.1 placebo count @ 1wkI
absolute change · count
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-2.4 vs -2.1 placebo count @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-2.5 vs -2.1 placebo count @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-3.1 vs -2.1 placebo count @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-4.7 vs -4.1 placebo count @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-4.9 vs -4.1 placebo count @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.4 vs -4.1 placebo count @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-3.9 vs -4.1 placebo count @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.1 vs -6.9 placebo count @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.8 vs -6.9 placebo count @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.6 vs -6.9 placebo count @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.2 vs -6.9 placebo count @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.3 vs -7.7 placebo count @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-10 vs -7.7 placebo count @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.7 vs -7.7 placebo count @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.8 vs -7.7 placebo count @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-10.3 vs -8.4 placebo count @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.3 vs -8.4 placebo count @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-10.7 vs -8.4 placebo count @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-9.8 vs -8.4 placebo count @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.2 vs -9.9 placebo count @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-12.3 vs -9.9 placebo count @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.5 vs -9.9 placebo count @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.4 vs -9.9 placebo count @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.9 vs -9.4 placebo count @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-12.6 vs -9.4 placebo count @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-12.9 vs -9.4 placebo count @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-12 vs -9.4 placebo count @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
Tender Joint Count -12.3 count @ 52wkI
absolute change · count
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more results
-13.7 count @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-16 count @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-14 count @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
Swollen Joint Count -1.8 vs -1.3 placebo count @ 1wkI
absolute change · count
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-2.1 vs -1.3 placebo count @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-1.3 vs -1.3 placebo count @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-2.4 vs -1.3 placebo count @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-4.1 vs -3.1 placebo count @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-3.8 vs -3.1 placebo count @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-3.8 vs -3.1 placebo count @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-3 vs -3.1 placebo count @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.8 vs -4.7 placebo count @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.5 vs -4.7 placebo count @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.7 vs -4.7 placebo count @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-5 vs -4.7 placebo count @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.3 vs -4.9 placebo count @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.6 vs -4.9 placebo count @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.2 vs -4.9 placebo count @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-4.8 vs -4.9 placebo count @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-8 vs -5.2 placebo count @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.2 vs -5.2 placebo count @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-7 vs -5.2 placebo count @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-6 vs -5.2 placebo count @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.3 vs -6 placebo count @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.4 vs -6 placebo count @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.4 vs -6 placebo count @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.8 vs -6 placebo count @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.3 vs -6.5 placebo count @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.7 vs -6.5 placebo count @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.2 vs -6.5 placebo count @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.6 vs -6.5 placebo count @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
Swollen Joint Count -8.7 count @ 52wkI
absolute change · count
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more results
-7.5 count @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-9.2 count @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.5 count @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
Physician Global Assessment -7.8 vs -4.5 placebo score @ 1wkI
absolute value · score
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-8 vs -4.5 placebo score @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.2 vs -4.5 placebo score @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.2 vs -4.5 placebo score @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-14.3 vs -9.7 placebo score @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-15.7 vs -9.7 placebo score @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-15.1 vs -9.7 placebo score @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-14 vs -9.7 placebo score @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-21.9 vs -16.2 placebo score @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.6 vs -16.2 placebo score @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.9 vs -16.2 placebo score @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-20.8 vs -16.2 placebo score @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-27.9 vs -18.5 placebo score @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-28.7 vs -18.5 placebo score @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-27.6 vs -18.5 placebo score @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.1 vs -18.5 placebo score @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-31 vs -20.2 placebo score @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-32.1 vs -20.2 placebo score @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-31.7 vs -20.2 placebo score @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-30.8 vs -20.2 placebo score @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-36.7 vs -24.3 placebo score @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-36.8 vs -24.3 placebo score @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-31 vs -24.3 placebo score @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-33 vs -24.3 placebo score @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-36.5 vs -23.5 placebo score @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-38.8 vs -23.5 placebo score @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-37.5 vs -23.5 placebo score @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-36.3 vs -23.5 placebo score @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
Physician Global Assessment -40 score @ 52wkI
absolute change · score
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more results
-44.3 score @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-45.3 score @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-42.7 score @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
Patient Global Assessment -5.9 vs -2.8 placebo score @ 1wkI
absolute value · score
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-7.5 vs -2.8 placebo score @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.8 vs -2.8 placebo score @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.4 vs -2.8 placebo score @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.5 vs -5.9 placebo score @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.9 vs -5.9 placebo score @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-9.5 vs -5.9 placebo score @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.8 vs -5.9 placebo score @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-15.4 vs -10.1 placebo score @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-15.5 vs -10.1 placebo score @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-14.5 vs -10.1 placebo score @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-13.1 vs -10.1 placebo score @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-18.1 vs -11.2 placebo score @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-20.3 vs -11.2 placebo score @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-16.1 vs -11.2 placebo score @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-16.4 vs -11.2 placebo score @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.5 vs -13.8 placebo score @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-22 vs -13.8 placebo score @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-18.7 vs -13.8 placebo score @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-19.4 vs -13.8 placebo score @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-29.7 vs -15.6 placebo score @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-27.3 vs -15.6 placebo score @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-22.7 vs -15.6 placebo score @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-21.6 vs -15.6 placebo score @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-35 vs -21.7 placebo score @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-33.3 vs -21.7 placebo score @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-33.4 vs -21.7 placebo score @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-30.4 vs -21.7 placebo score @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
Patient Global Assessment -42.2 score @ 52wkI
absolute change · score
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more results
-43.8 score @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-38.4 score @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-37.9 score @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
Patient Pain VAS -5.8 vs -1.6 placebo score @ 1wkI
absolute value · score
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-8.1 vs -1.6 placebo score @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.1 vs -1.6 placebo score @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.8 vs -1.6 placebo score @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-9.8 vs -3.9 placebo score @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-12.8 vs -3.9 placebo score @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.9 vs -3.9 placebo score @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.4 vs -3.9 placebo score @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-16.9 vs -8.5 placebo score @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-16.1 vs -8.5 placebo score @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-16.6 vs -8.5 placebo score @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.9 vs -8.5 placebo score @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-19.4 vs -11.5 placebo score @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-20.4 vs -11.5 placebo score @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-15.6 vs -11.5 placebo score @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-14 vs -11.5 placebo score @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.8 vs -12.8 placebo score @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.2 vs -12.8 placebo score @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-20.6 vs -12.8 placebo score @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-19.3 vs -12.8 placebo score @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-29.8 vs -17.1 placebo score @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-25.3 vs -17.1 placebo score @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-21.4 vs -17.1 placebo score @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-21.4 vs -17.1 placebo score @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-35.1 vs -21.5 placebo score @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-31.6 vs -21.5 placebo score @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-32.1 vs -21.5 placebo score @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-28.8 vs -21.5 placebo score @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
Pain VAS -40.7 score @ 52wkI
absolute change · score
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more results
-42.7 score @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-38 score @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-37.6 score @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
HAQ-DI -0.0374 vs -0.0045 placebo score @ 1wkI
absolute value · score
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-0.0453 vs -0.0045 placebo score @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.0552 vs -0.0045 placebo score @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.0411 vs -0.0045 placebo score @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.0025 vs -0.0404 placebo score @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.0736 vs -0.0404 placebo score @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.0906 vs -0.0404 placebo score @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.0409 vs -0.0404 placebo score @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.151 vs -0.1265 placebo score @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.1279 vs -0.1265 placebo score @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.2035 vs -0.1265 placebo score @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.1041 vs -0.1265 placebo score @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.131 vs -0.1374 placebo score @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.214 vs -0.1374 placebo score @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.209 vs -0.1374 placebo score @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.1731 vs -0.1374 placebo score @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.2061 vs -0.158 placebo score @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.2448 vs -0.158 placebo score @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.2343 vs -0.158 placebo score @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.2102 vs -0.158 placebo score @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.3052 vs -0.2271 placebo score @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.2868 vs -0.2271 placebo score @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.2911 vs -0.2271 placebo score @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.1947 vs -0.2271 placebo score @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.3013 vs -0.1827 placebo score @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.3314 vs -0.1827 placebo score @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.3337 vs -0.1827 placebo score @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.2376 vs -0.1827 placebo score @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · tildrakizumab's landscape